Back to results
US 9,011,937 B2Granted
Method of treating neurological conditions with extract of Nerium species or Thevetia species
AssigneePhoenix Biotechnology, Inc.
InventorsOtis C. Addington, Robert A. Newman
Life of this patent
Estimating the term…
Abstract
A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of Nerium species or Thevetia species is provided, wherein the extract, or fraction or sub-fraction thereof, excludes oleandrin and neriifolin. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of the extract, or a fraction or sub-fraction thereof, to a subject. The extract can be present in a pharmaceutical composition.
Claims30
A method of treating a neurological condition in a subject comprising:
- administering to a subject in need thereof a composition comprising an extract of Nerium species or of Thevetia species in an effective amount to treat said neurological condition, wherein the extract comprises as major components at least one steroid and at least one triterpene extracted from the Nerium species or Thevetia species, comprises less than 1% wt. of polysaccharide extracted from the Nerium species or Thevetia species, and the extract excludes oleandrin and neriifolin, wherein the neurological condition is selected from the group consisting of Huntington's disease, stroke, a taupathy or a condition having an etiology associated with excessive proteolysis of amyloid beta precursor protein, with accumulation of amyloid beta protein in the synapses of the neurons of a subject, with formation of amyloid fibrils in the synapses of the neurons of a subject, or with formation of amyloid plaques in the synapses of the neurons of a subject, wherein the neurological condition excludes Alzheimer's disease and multiple sclerosis.
A method for improving the clinical status of a statistically significant number of subjects of in a population of subjects having a neurological condition, the method comprising:
- administering to the population of subjects an extract of Nerium species or of Thevetia species, wherein the extract is unfractionated, a fraction thereof or a sub-fraction or a fraction thereof;
- and determining the clinical status of the subjects, wherein the extract, fraction thereof or sub-fraction thereof comprises as major components at least one steroid and at least one triterpene extracted from the Nerium species or Thevetia species, comprises less than 1% wt. of polysaccharide extracted from the Nerium species or Thevetia species, and excludes oleandrin and neriifolin, and wherein the neurological condition excludes Alzheimer's disease and multiple sclerosis.
A method of reducing the incidence of occurrence of a neurological condition in a population of subjects at risk thereof, the method comprising
- administering an effective dose of extract, fraction thereof or sub-fraction thereof of Nerium species or Thevetia species on a recurring basis for an extended period of time to one or more subjects in a population of subjects at risk of suffering from a neurological condition selected from the group consisting of Huntington's disease and stroke, thereby reducing the incidence of the neurological condition in the population, wherein the extract, fraction thereof or sub-fraction thereof comprises as major components at least one steroid and at least one triterpene extracted from the Nerium species or Thevetia species, comprises less than 1% wt. of polysaccharide extracted from the Nerium species or Thevetia species, and excludes oleandrin and neriifolin, and wherein the neurological condition excludes Alzheimer's disease and multiple sclerosis.
A time-delayed method of treating stroke in a subject comprising:
- within a delay period after a subject has suffered the stroke, administering an initial dose of extract, or fraction thereof or sub-fraction thereof of Nerium species or Thevetia species according to an initial dosing regimen, wherein the extract, fraction thereof or sub-fraction thereof comprises as major components at least one steroid and at least one triterpene extracted from the Nerium species or Thevetia species, comprises less than 1% wt. of polysaccharide extracted from the Nerium species or Thevetia species, and excludes oleandrin and neriifolin;
- determining the adequacy of subject's clinical response and/or therapeutic response to treatment with the extract;
- and
- if the subject's clinical response and/or therapeutic response is adequate, then continuing treatment with extract as needed until the desired clinical endpoint is achieved;
- or
- if the subject's clinical response and/or therapeutic response are inadequate at the initial dose and initial dosing regimen, then escalating or deescalating the dose until the desired clinical response and/or therapeutic response in the subject is achieved.
3 more elements
A method of treating a neurological condition in a subject comprising:
- administering to a subject in need thereof a composition comprising an extract of Nerium species or of Thevetia species in an effective amount to treat said neurological condition, wherein the extract comprises one or more therapeutically effective agents extracted from the Nerium species or Thevetia species, comprises less than 1% wt. of polysaccharide extracted from the Nerium species or Thevetia species and the extract excludes oleandrin and neriifolin, and wherein the extract, or fraction thereof or sub-fraction thereof, of Nerium species or Neriifolia species, has a 1HNMR spectrum as described in FIGS. 9B-9I.
A method of treating a neurological condition in a subject comprising:
- administering to a subject in need thereof a composition comprising an extract of Nerium species or of Thevetia species in an effective amount to treat said neurological condition, wherein the extract comprises one or more therapeutically effective agents extracted from the Nerium species or Thevetia species, comprises less than 1% wt. of polysaccharide extracted from the Nerium species or Thevetia species and the extract excludes oleandrin and neriifolin, and wherein the extract, or fraction thereof or sub-fraction thereof, of Nerium species or Neriifolia species, has a HPLC chromatogram as described in FIG. 8D.
Dependencies are inferred from the claim text.